Monday said federal regulators have approved its atypical antipsychotic drug for new uses.
Specifically, the drug, Geodon, was OK'd for the treatment of acute bipolar mania including manic and mixed episodes.
The approval comes after tests showed the drug rapidly improved acute manic symptoms and sustained the improvements over a three-week study period. Unlike other bipolar medications, Pfizer said Geodon did not cause substantial weight gain.
Geodon was previously approved for the treatment of schizophrenia in 2001. Pfizer said the drug is licensed in 67 countries with more than 3 million prescriptions already written.
Pfizer shares gained 15 cents, or 0.5%, to $31.89.